Suzhou Basecare Medical (HKSE:02170) Cyclically Adjusted PS Ratio: (As of Sep. 10, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HKSE:02170 Suzhou Basecare Medical Corp Ltd HKSE:02170
68 GF Score
Price HK$1.35
GF Value HK$2.98
Valuation Possible Value Trap
! 7 Warning Signs
View Full Analysis

What is Suzhou Basecare Medical Cyclically Adjusted PS Ratio?

Suzhou Basecare Medical does not have a history long enough to calculate Cyclically Adjusted Revenue per Share. Therefore GuruFocus does not calculate Cyclically Adjusted PS Ratio for this company.

Shiller PE for Stocks: The True Measure of Stock Valuation


Suzhou Basecare Medical  (HKSE:02170) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Suzhou Basecare Medical Cyclically Adjusted PS Ratio Related Terms


Suzhou Basecare Medical Cyclically Adjusted PS Ratio Historical Data

* Premium members only.

The historical data trend for Suzhou Basecare Medical's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Suzhou Basecare Medical Cyclically Adjusted PS Ratio Chart

Suzhou Basecare Medical Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

Suzhou Basecare Medical Semi-Annual Data
Dec18 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

HKSE:02170 vs ABT, SYK, MDT: Cyclically Adjusted PS Ratio Comparison

For the Medical Devices subindustry, Suzhou Basecare Medical's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Suzhou Basecare Medical Cyclically Adjusted PS Ratio vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Suzhou Basecare Medical's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Suzhou Basecare Medical's Cyclically Adjusted PS Ratio falls into.


HKSE:02170
68GF Score
Suzhou Basecare Medical Corp Ltd HKSE:02170
Cyclically Adjusted PS Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Suzhou Basecare Medical Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Suzhou Basecare Medical does not have a history long enough to calculate Cyclically Adjusted Revenue per Share. Therefore GuruFocus does not calculate Cyclically Adjusted PS Ratio for this company.

Is Suzhou Basecare Medical (HKSE:02170) Overvalued in 2026?

Based on GuruFocus' analysis, Suzhou Basecare Medical stock appears to be undervalued. The current stock price of HK$1.35 is trading 54.7% below its estimated GF Value™ of HK$2.98. GuruFocus considers Suzhou Basecare Medical to be Possible Value Trap.

Key valuation signals for HKSE:02170:

  • Cyclically Adjusted PS Ratio:
  • GF Value™: HK$2.98 vs. price of HK$1.35 (54.7% below fair value)
  • GF Score™: 68/100 with 7 warning signs

No single metric tells the full story. See the HKSE:02170 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Suzhou Basecare Medical Business Description

Address No. 77 Jingu Road, Suzhou Industrial Park, Jiangsu Province, Suzhou, CHN
Suzhou Basecare Medical Corp Ltd is a medical device company based in China, operating in the field of assisted reproduction. It is engaged in the research, development, and provision of medical products and related software in the field of reproductive health, to enable more families to have children. The Group's product portfolio comprises Gems Sperm Wash Gradient Set, Gems Fertilisation Medium, Gavi Instrument, Geri Incubator, Cryostorage System, PGT-A kit, Self sperm testing device, Sperm quality analyser, Genie sequencer, and others. It generates maximum revenue from the sale of testing kits. The Group's reportable segments are: the PRC, which derives maximum revenue, and Australia. Geographically, it operates in the PRC, Europe, Asia (excluding the PRC), and other regions.
68GF Score

Get the complete analysis for HKSE:02170

Cyclically Adjusted PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$1.35
Price
HK$2.98
GF Value